jeudi 23 août 2018

Onco Actu du 23 août 2018

1. Biologie

The cartographer of cells [MIT Technology Review]


Bladder Cancer Contrast [Harvard Medical School]

4. Dépistage, diagnostic et pronostic

A New Device to Monitor Heart Dysfunction in Childhood Cancer Survivors [Cancer Research Catalyst]

4.1 Dép., diag. & prono. - Prostate

Men, Beware of Biopsies for Prostate Cancer Dx [MedPage Today]

4.2 Dép., diag. & prono. - Génome

Gene testing of Nigerian women could help prevent breast cancer [UW Medicine]

4.5 Dép., diag. & prono. - Colorectal

Exact Sciences signs marketing deal with Pfizer for cancer test [Reuters]

5. Traitements

Lasers help fight deadly brain tumors [WUSTL]

5.10 Traitements - Essais

Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate Cancer [Pfizer]

5.12 Immunothérapies

CancerLinQ LLC, Concerto HealthAI, and Tempus are Expanding Collaboration with U.S. Food and Drug Administration on Checkpoint Inhibitors [ASCO]

Immunotherapy Drugs Slow Skin Cancer That Has Spread to the Brain [NY Times]

5.12.1 Immunothérapies - partenariats

$60M in, AbbVie is triggering a $625M-plus plan to develop a new immuno-oncology drug that is going after GARP [EndPoints]

argenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology antibody [argenx]

AbbVie doubles down on cancer project with biotech group Argenx [Reuters]

5.12.2 Immunothérapies - CAR-T, thérapies cellulaires

Cell and Gene Therapy Tracker: Global CAR T-Cell Trials [The Scientist]

5.12.8 Immunothérapies - Economie

Bristol-Myers will sell Opdivo in China at half of US cost, setting precedent for checkpoint wave — report [EndPoints]

5.2 Pharma

Novartis trial win lifts profile of new breast cancer drug [Reuters]

5.3 Traitements - FDA, EMA, NICE...

Real-Time Approval [In the Pipeline]

6. Lutte contre les cancers

Radiologist shortage 'affecting cancer care' in the UK [BBC News]